马静;赵雯红;袁世发;黄丽珍;张佳佳;程建新;

• 1:河北医科大学第四医院妇科
• 2:河北武警总队医院普外科
• 3:北京大学第三医院妇产科

摘要(Abstract)：

目的:探讨NK-1受体拮抗剂对子宫内膜癌Ishikawa细胞增殖、凋亡、细胞周期及侵袭影响。方法:体外培养子宫内膜腺癌Ishikawa细胞,将不同浓度NK-1受体拮抗剂与其共培养48h后,采用MTT法检测Ishikawa细胞增殖情况;采用流式细胞术检测细胞凋亡率及细胞周期分布;利用Transwell实验检测细胞侵袭能力。结果:NK-1受体拮抗剂可明显抑制Ishikawa细胞增殖(P<0.05);促进细胞凋亡,使细胞周期中G0/G1期比例增加,S期及G2/M期比例降低(P均<0.05);抑制细胞侵袭,并且其对Ishikawa细胞的这些作用均呈剂量依赖性。结论:NK-1受体拮抗剂可明显抑制子宫内膜癌细胞增殖、阻滞细胞周期、诱导凋亡及抑制侵袭,有望成为子宫内膜细胞治疗的新途径。

关键词(KeyWords)： 神经激肽1;子宫内膜癌;细胞凋亡;增殖;侵袭

Abstract:

Keywords:

基金项目(Foundation): 河北省卫生和计划生育委员会医学科学研究重点课题(No:20150337)

作者(Authors): 马静;赵雯红;袁世发;黄丽珍;张佳佳;程建新;

DOI: 10.13283/j.cnki.xdfckjz.2016.07.009

参考文献(References)：

• [1]Makker A,Goel MM.Tumor progression,metastasis,and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma:an update[J].Endocr Relat Cancer,2016,23(2):85-111
• [2]Colombo N,Preti E,Landoni F,et al.Endometrial cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24(6):33-38
• [3]Lambreeht BN.Immunologists getting nervous:neuropeptides,dendritic cells and T ceel activation[J].Respir Res,2001,2(3):133-138
• [4]Deans RJ,Moseley AB.Mesenchymal stem cells:biology and potential clinical uses[J].Exp Hematol,2000,28(8):875-884
• [5]Chen P,Douglas SD,Meshki J,et al.Neurokinin 1 receptor mediates membrance blebbing and sheer stress-induced microparticle formation in HEK293 cells[J].Plo S One,2012,7(9):e45322
• [6]Munoz M,Gonzalez-Ortega A,Rosso M,et al.The substance P/neurokinin-1 receptor system in lung cancer:focus on the antitumor action of neurokinin-1 receptor antagonists[J].Peptides,2012,38(2):318-325
• [7]Feng F,Yang J,Tong L,et al.Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells.Cell Biol Int,2011,35(6):623-629
• [8]Harford-Wright E,Lewis KM,Ghabriel MN,et al.Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors[J].Plo S One,2014,9(5):e97002
• [9]Zhou Y,Zhao L,Xiong T,et al.Role of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer[J].Breast Cancer Res Treat,2013,140(1):49-61
• [10]Berger M,Neth O,Ilmer M,et al.Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo[J].J Hepatol,2014,60(5):985-994
• [11]Munoz M,Covenas R.Involvement of substance P and NK-1 receptor in pancreatic cancer[J].World J Gastroenterol,2014,20(9):2321-2334
• [12]Kohara H,Tajima S,Yamanoto M,et al.Angiogenesis induced by controlled release of neuropeptide substance P[J].Biomaterials,2010,31(33):8617-8625
• [13]Munoz M,Rosso M,Covenas R.The NK-1 receptor:a new target in cancer therapy[J].Curr Drug Targers,2011,12(6):909-921
• [14]Li X,Ma G,Ma Q,et al.Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells[J].Mol Cancer Res,2013,11(3):294-302
• [15]Garcia-Recio S,Fuster G,Fernandez-Nogueira P,et al.Substance P autocrine signaling contributes to persistent HER2 activation that derives malignant progression and drug resistance in breast cancer[J].Cancer Res,2013,73(21):6424-6434
• [16]Esteban F,Munoz M,Gonzalez-Moles MA,et al.A role for substance P in cancer promotion and progression:a mechanism to counteract intracellular death signals following oncogene activation or DNA damage[J].Cancer Metastasis Rev,2006,25(1):137-145